LLY

1,066.57

-0.02%↓

JNJ

230.23

-1.85%↓

ABBV

212.63

-1.61%↓

UNH

377.52

-2.74%↓

AZN

187.14

-0.06%↓

LLY

1,066.57

-0.02%↓

JNJ

230.23

-1.85%↓

ABBV

212.63

-1.61%↓

UNH

377.52

-2.74%↓

AZN

187.14

-0.06%↓

LLY

1,066.57

-0.02%↓

JNJ

230.23

-1.85%↓

ABBV

212.63

-1.61%↓

UNH

377.52

-2.74%↓

AZN

187.14

-0.06%↓

LLY

1,066.57

-0.02%↓

JNJ

230.23

-1.85%↓

ABBV

212.63

-1.61%↓

UNH

377.52

-2.74%↓

AZN

187.14

-0.06%↓

LLY

1,066.57

-0.02%↓

JNJ

230.23

-1.85%↓

ABBV

212.63

-1.61%↓

UNH

377.52

-2.74%↓

AZN

187.14

-0.06%↓

Home・Akciju saraksts・Medtronic PLC

Search

Medtronic PLC

Slēgts

SektorsVeselības aprūpe

77.53 -1.42

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

77.53

Max

78.6

Galvenie mērījumi
By Trading Economics
Ienākumi	-231M 1.1B
Pārdošana	57M 9B
P/E Sektora vidējais	21.598 49.701
EPS	0.89
Dividenžu ienesīgums	3.72
Peļņas marža	12.675
Darbinieki	95,000
EBITDA	124M 2.5B

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt
Prognoze 12 mēnešiem	+33.44% upside

Dividendes
By Dow Jones
Dividenžu ienesīgums Sektora vidējais	3.72% 2.39%
Nākamie ieņēmumi	2026. g. 3. jūn.
Nākamais dividenžu datums	2026. g. 10. jūl.
Nākamais Ex dividenžu datums	2026. g. 26. jūn.

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	-28B 99B
Iepriekšējā atvēršanas cena	78.95
Iepriekšējā slēgšanas cena	77.53

Ziņu noskaņojums

By Acuity

24%

76%

45 / 344 Rangs Healthcare

Medtronic PLC Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 20. maijs 13:49 UTC

Iegādes, apvienošanās, pārņemšana

Medtronic to Buy SPR Therapeutics for About $650 Million

2026. g. 10. marts 11:19 UTC

Iegādes, apvienošanās, pārņemšana

Medtronic to Buy Scientia Vascular in $550 Million Deal

2026. g. 17. febr. 12:43 UTC

Peļņas

Medtronic 3Q Profit Falls Despite Higher Revenue

2026. g. 20. maijs 13:15 UTC

Iegādes, apvienošanās, pārņemšana

Medtronic Announces Intent To Acquire SPR Therapeutics, Inc., Expanding Care Options For People Living With Chronic Pain >MDT

2026. g. 20. maijs 13:15 UTC

Iegādes, apvienošanās, pārņemšana

Medtronic to Buy SPR Therapeutics for About $650 Million in Cash >MDT

2026. g. 22. apr. 11:27 UTC

Peļņas

Intuitive Surgical Earnings Show Big Beats Don't Always Spark Stock Rallies -- Barrons.com

2026. g. 20. apr. 11:50 UTC

Iegādes, apvienošanās, pārņemšana

Medtronic Completes Acquisition Of CathWorks, Expanding Its Leadership In Transforming Care For Patients With Cardiovascular Disease >MDT

2026. g. 24. marts 20:59 UTC

Peļņas

Medtronic PLC Cuts FY26 View To Adj EPS $5.50-Adj EPS $5.54 >MDT

2026. g. 10. marts 10:46 UTC

Iegādes, apvienošanās, pārņemšana

Medtronic: Scientia Deal Complements Neurovascular Portfolio >MDT

2026. g. 10. marts 10:46 UTC

Iegādes, apvienošanās, pārņemšana

Medtronic: Scientia Deal Includes Potential Undisclosed Earn-Out, Milestone Payments >MDT

2026. g. 10. marts 10:45 UTC

Iegādes, apvienošanās, pārņemšana

Medtronic: Scientia Vascular Acquisition Valued at $550 Million >MDT

2026. g. 10. marts 10:45 UTC

Iegādes, apvienošanās, pārņemšana

Medtronic to Acquire Scientia Vascular >MDT

2026. g. 17. febr. 21:21 UTC

Peļņas

These Stocks Are Today's Movers: Paramount, Masimo, Medtronic, Kyndryl, eToro, Genuine Parts, Southwest, and More -- Barrons.com

2026. g. 17. febr. 18:11 UTC

Peļņas

Medtronic Posts Better-Than-Expected Earnings. Here's Why the Stock Is Falling. -- Barrons.com

2026. g. 17. febr. 14:48 UTC

Peļņas

Medtronic Posts Better-Than-Expected Earnings. Here's Why the Stock Is Falling. -- Barrons.com

2026. g. 17. febr. 13:00 UTC

Peļņas

Medtronic Posts Better-Than-Expected Earnings. Here's Why the Stock Is Falling. -- Barrons.com

2026. g. 17. febr. 12:05 UTC

Peļņas

Medtronic Posts Better-Than-Expected Earnings. Here's Why the Stock Is Falling. -- Barrons.com

2026. g. 17. febr. 11:47 UTC

Peļņas

Medtronic Sees 2026 EPS up 4.5%, Excluding Potential Impact From Tariffs >MDT

2026. g. 17. febr. 11:47 UTC

Peļņas

Medtronic Still Sees FY26 Organic Revenue Up About 5.5% >MDT

2026. g. 17. febr. 11:46 UTC

Peļņas

Medtronic FY26 View Includes Potential Impact From Tariffs of About $185M >MDT

2026. g. 17. febr. 11:46 UTC

Peļņas

Medtronic Backs FY26 View of Adj EPS $5.62-Adj EPS $5.66 >MDT

2026. g. 17. febr. 11:46 UTC

Peļņas

Medtronic Reiterates FY26 Organic Rev Growth, EPS Guidance >MDT

2026. g. 17. febr. 11:45 UTC

Peļņas

Medtronic 3Q Adj EPS $1.36 >MDT

2026. g. 17. febr. 11:45 UTC

Peļņas

Medtronic 3Q Neuroscience Portfolio Rev $2.56B >MDT

2026. g. 17. febr. 11:45 UTC

Peļņas

Medtronic 3Q Organic Revenue Up 6.0% >MDT

2026. g. 17. febr. 11:45 UTC

Peļņas

Medtronic 3Q Sales $9.02B >MDT

2026. g. 17. febr. 11:45 UTC

Peļņas

Medtronic 3Q Diabetes Rev $796M >MDT

2026. g. 17. febr. 11:45 UTC

Peļņas

Medtronic 3Q Cardiovascular Portfolio Rev $3.46B >MDT

2026. g. 17. febr. 11:45 UTC

Peļņas

Medtronic 3Q Medical Surgical Portfolio Rev $2.17B >MDT

2026. g. 17. febr. 11:45 UTC

Peļņas

Medtronic 3Q Net $1.14B >MDT

Salīdzinājums

Cenas izmaiņa

Medtronic PLC Prognoze

Cenas mērķis

By TipRanks

33.44% augšup

Prognoze 12 mēnešiem

Vidējais 104.88 USD 33.44%

Augstākais 120 USD

Zemākais 84 USD

Pamatojoties uz 18 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Medtronic PLC — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

18 ratings

11

Pirkt

7

Turēt

0

Pārdot

Pamatojoties uz 18 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Medtronic PLC — pēdējo 3 mēnešu laikā.

Noskaņojums

By Acuity

45 / 344 Rangs Veselības aprūpe

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Medtronic PLC

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. The Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves; and percutaneous coronary intervention products, percutaneous angioplasty balloons, and other products. The Neuroscience Portfolio segment offers medical devices and implants, biologic solutions, spinal cord stimulation and brain modulation systems, implantable drug infusion systems, and interventional products, as well as nerve ablation system under the Accurian name. The segment offers its products for spinal surgeons, neurosurgeons, neurologists, pain management specialists, anesthesiologists, orthopedic surgeons, urologists, urogynecologists, and interventional radiologists, as well as ear, nose, and throat specialists; and energy surgical instruments. The Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure and electrosurgery products, AI-powered surgical video and analytics platform, robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology products, gastrointestinal and hepatologic diagnostics and therapies, and therapies to treat other non-exclusive diseases and conditions; and patient monitoring and airway management products. The Diabetes Operating Unit segment provides insulin pumps and consumables, continuous glucose monitoring systems, and InPen, a smart insulin pen system. The company was founded in 1949 and is headquartered in Galway, Ireland.

Citi krājumi no sektora

LLY

Eli Lilly and Co.

1,066.57

JNJ

Johnson and Johnson

230.23

ABBV

AbbVie Inc

212.63

UNH

UnitedHealth Group Inc

377.52

AZN

AstraZeneca PLC

187.14

Live chat